Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

Deuruxolitinib effectively promotes hair regrowth in alopecia areata.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This review summarizes current knowledge on the role of the JAK/STAT signaling pathway in alopecia areata and suggests moderate efficacy of systemic inhibitors, with low adverse events but high recurrence rates.

This study found that a lotion containing specific plant extracts significantly increased the number of anagen hairs and the anagen/telogen ratio in subjects with androgenetic alopecia after three months of use.

This review discusses the FDA-approved JAK inhibitor baricitinib as a treatment for alopecia areata, highlighting its dosing regimen, clinical challenges, and the need for additional safety data while exploring the potential of other topical and sublingual JAK inhibitors under investigation.

This study suggests that particulate matter can induce inflammation in human outer root sheath cells, potentially affecting hair growth, through oxidative stress-dependent MAPK and JAK-STAT signaling pathways.

This review discusses recent findings on the efficacy of JAK inhibitors for treating alopecia areata, highlighting their role in reversing hair loss by targeting the JAK-STAT signaling pathway, though questions about their effectiveness and safety remain.

This case report describes a 43-year-old male patient with alopecia totalis successfully regaining all his hair after six months of treatment with tofacitinib, with no relapse observed after one year.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

This study suggests that oral JAK inhibitors can be an effective treatment option for approximately half of patients with moderate to severe alopecia areata, despite variable responses and potential adverse effects.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

This study found that JAK1 and JAK3 inhibitors effectively reversed alopecia in a mouse model of AA by reducing skin inflammation, while JAK2 inhibition did not promote hair regrowth.

Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.

This study identified a specific subset of macrophages as a key source of oncostatin M, maintaining hair follicle stem cell quiescence during the resting phase in mice, suggesting a potential target for treating hair disorders.

This study found that knocking out STAT5 expression in specific mouse hair follicles after tamoxifen treatment initiated uniform hair growth, highlighting STAT5's role in regulating the hair growth cycle.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This study found that inhibiting JAK signaling can unexpectedly trigger hair growth in resting-phase mouse skin, implicating JAK-STAT pathways and oncostatin M in maintaining hair follicle stem cell quiescence.

In this study, quercetin and kaempferol, two plant-derived flavonoids, showed stronger binding affinities to JAK3 kinase and moderate binding to 5-alpha reductase type 2, suggesting their potential as natural treatments for androgenetic alopecia, with quercetin demonstrating suitable properties for topical application.

This study used molecular docking to analyze the binding affinities of quercetin and kaempferol, plant-derived flavonoids, showing they have promising interaction profiles with JAK3 kinase and moderate binding with 5-alpha reductase type 2, suggesting potential as topical treatments for androgenetic alopecia.

In this study, the bark extract of Albizia saponaria was analyzed for its metabolites and potential anti-alopecia effects, identifying several compounds with predicted affinities for proteins involved in hair loss pathways.

This study found that the JAK1 rs310241 AG genotype is associated with a 4.6-fold increased risk of alopecia areata, whereas JAK2 polymorphisms showed no significant link, suggesting a potential genetic susceptibility factor warranting further research.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

This research found that kaempferol, a flavonoid from hair growth-promoting plants, significantly enhanced human dermal papilla cell proliferation and inhibited specific signaling pathways, outperforming minoxidil, with topical application in mice promoting hair growth and thickness, indicating potential as a natural hair loss treatment.

This study examined molecular predictors of ritlecitinib efficacy in treating alopecia areata, highlighting the role of JAK3-dependent inflammation and follicular integrity as important factors in understanding disease mechanisms and potential therapeutic effectiveness.

In this study, the researchers identified MJ04, a selective JAK3 inhibitor, as a promising candidate for promoting hair growth, demonstrating efficacy in both animal models and human hair follicle assays with a favorable safety and pharmacokinetic profile.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study found that OR-101, a selective JAK3/TEK inhibitor, was associated with dose-dependent improvements in hair growth in humanized mice with alopecia areata, suggesting its potential as a treatment option.

This study predicted that 6-hydroxy genistein, coreximine, and scoulerine from Dadap leaves may act as anti-alopecia agents by interacting with JAK2, but further in-vivo testing is needed.